Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Exercise of warrants, conversion of convertible loan

Reference is made to the stock exchange notice by Solstad Offshore ASA (the "Company") dated 17 December 2021 regarding the sale of the vessel "Far Scout" (the "Vessel"). Further reference is made to the warrants issued to certain banks by decision of the Company's general meeting held on 20 October 2020 giving such banks (as well as other banks) the right to receive new shares in the Company as compensation for any part of their claim against SOFF related to certain vessels (including the Vessel) not covered by the proceeds from the sale of such vessels (the "Warrants"). Reference is also

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 14 - 17 JANUARY 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 75/2021. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

DAMPSKIBSSELSKABET NORDEN A/S – WEEKLY REPORT ON SHARE BUY-BACK

ANNOUNCEMENT NO. 13 - 17 JANUARY 2022 On 4 November 2021, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 4 November 2021 up to and including no later than end February 2022. For details, please see announcement no. 75 of 4 November 2021. Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 40 million (approximately DKK 263 million).

WntResearch files a patent application expanding the commercial potential of Foxy-5

WntResearch is broadening its potential patent protection according to the commercial strategy by filing an international patent application that covers new stable compositions with high solubility of its candidate drug Foxy-5.As an integral part of our commercial strategy, WntResearch has for the past year been working on different approaches for addressing the known limited solubility of Foxy-5 with the clear aim of identifying a new dosage form for further pivotal clinical studies and the future commercial launch. We have now succeeded in producing several new compositions of Foxy-5

Oxcia contracts Patheon for manufacturing and further strengthens the organization

Oxcia, a pioneer in oxidative DNA damage and DNA Damage Response (DDR) with a focus on developing new safe treatments for cancer and inflammation, has contracted Patheon for upscaling and production of OXC-101 substance and tablets for the upcoming Phase 2 clinical trials. OXC-101 is Oxcia's first-in-class anticancer drug candidate, currently in phase 1 studies in patients with advanced solid cancers or blood cancers.   Patheon is part of the global ThermoFisher Scientific Group and is a leading contract manufacturer with production in several countries.   Oxcia continues to

Scandic to open climate-neutral hotel in Sundsvall in 2024

Scandic Hotels has signed a long-term lease agreement with Skanska for a new 210-room hotel in downtown Sundsvall. The new hotel, which will be attractively located in the city’s harbor area, will be built of wood, giving it a very high environmental standard. The hotel is expected to open during 2024. The hotel will be called Scandic Sundsvall Central.The hotel, which will be ideally located next to Sundsvall’s harbor and railway station, will have 210 rooms and a cozy restaurant and bar area on the ground floor. One floor up, guests will be able to enjoy the hotel’s spa and wellness

Gradientech starts decisive clinical study in Europe for QuickMIC®

Uppsala, 17 January, 2022. Gradientech AB (publ) announces the start of the clinical study of its diagnostic QuickMIC® system. The clinical study coordinated by the company is aimed to prove the clinical performance of the system and will form the basis for its regulatory CE-IVD approval prior to market launch. The QuickMIC system is developed with the aim to become the fastest diagnostic system on the market for antibiotic susceptibility testing of sepsis samples.QuickMIC is a diagnostic system for ultrarapid testing of antibiotic resistance intended for clinical microbiology laboratories.

Lumera appoints Lars Stugemo to Board of Directors

News release, Stockholm, January 17, 2022 – Lumera, a leading insurtech company dedicated to the digital transformation of the European life and pensions industry, has appointed Lars Stugemo to its Board of Directors.One of Sweden’s most recognized tech entrepreneurs, Lars Stugemo is the co-founder and former President and CEO of the IT and management consulting firm HiQ International. After more than 25 years with the company and two decades as CEO, Stugemo left HiQ in 2020. He has since been committed to advisory roles, including that as a board member and management consultant. “We

Aiforia appoints VP of Sales, Americas

Incoming VP brings over 20 years experience in the healthcare industry to help accelerate further business growth at Aiforia.Aiforia, a technology company providing deep learning AI software for image analysis in pathology in clinical diagnostics and preclinical analysis, today announced that Marco Comianos has joined the company as VP of Sales, Americas. Comianos will oversee sales efforts, as well as driving new business, revenue growth, and more partnerships with top hospitals and pharma companies across the region.   Over 3,000 users in over 50 countries are active users of

Cline Scientific extends collaboration agreement with AstraZeneca

As previously communicated, Cline Scientific AB is taking part in a collaboration with AstraZeneca to utilize Cline’s gradient technology as part of the multi-country European MSCA-ITN network, V.A Cure project. The parties have now agreed to continue this collaboration through 2022.The collaboration began in January 2021 and has been focused on using Cline’s gradient surface technology and methodology to develop protocols for differentiation of induced pluripotent stem (iPS) cells into cell types relevant for the repair and treatment of vascular anomalies. Creating such cell types will

Metsä Group selects the first projects to be funded as part of its nature management programme

Metsä Group press release 17 January 2022In the autumn of 2021, Metsä Group launched a ten-year programme to support regionally effective development projects that are carried out outside commercial Finnish forests and support biodiversity and the state of waters. The projects may relate to bird waters and wetlands, watercourse routes, small waters and coastal environments, pollinator habitats or new water protection methods. Nearly 40 projects took part in the first round of applications, which ended in late November 2021. The following projects were the first to be selected for the

Hynion becomes Sweden's largest supplier of hydrogen fuel for vehicles

Hynion has entered into an agreement to supply buses in Sandviken, Sweden, with hydrogen and, at the same time, takes over Linde's hydrogen filling station in Sandviken to provide hydrogen fuel to buses as well as to the cars. With the acquisition of the hydrogen station in Sandviken, Hynion will become Sweden's largest supplier of zero-emission hydrogen fuel. With three stations in Gothenburg, Stockholm and Sandviken, the company now has a good starting point for developing the hydrogen market in the transport sector.The transportation company Transdev has recently invested in two

DanCann Pharma A/S: Strong Support from the DanCann Pharma Board of Directors, who convert their warrants into shares and buy more than 80,000 shares equaling DKK +400,000

COPENHAGEN, Denmark, 17 January 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the Company has received great support from the Board of Directors in the latest transaction, where the Board of Directors has bought shares for more than DKK +400,000 in DanCann Pharma, equal more than +80,000 shares.The members of the Board of Directors of DanCann Pharma have decided to convert their warrants into shares in the Company. Chairman of the Board Carsten Trads, Per Wester, Magnus Østergaard Dahlmann and

DanCann Pharma A/S Announces Exercise of Warrants for Proceeds of DKK approx. DKK 9.3 million to Strengthen the Financial Position

COPENHAGEN, Denmark, 17 January 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the Company and 18 of its warrant-holders have exercised a total of 1,917,271 warrants issued pursuant to the terms set out in Schedules 6.5.1 and 7.1 of the Articles of Association.The warrant holders have exercised a total of 1,917,271 warrants issued pursuant to the terms set out in Schedules 6.5.1 and 7.1 of the Articles of Association. These warrants are exercised based on an agreement between DanCann Pharma and the

BioStock: Positive interim results from Spago Nanomedical

Lund-based company Spago Nanomedical recently announced interim results from their phase I study with SpagoPix, the tumour selective contrast agent in cancer diagnostics with magnetic resonance imaging. The results show that the candidate is safe, that it accumulates into the tumours, and that it provides clear contrast enhancement in the image analysis. Based on these results the company has decided to expand the study to new indications, in addition to breast cancer. BioStock reached out to CEO Mats Hansen for a comment.Read the interview with Spago Nanomedical's CEO Mats Hansen at

Episurf’s implants approved for sale in Malaysia

Episurf Medical (NASDAQ: EPIS B) today announces that the Medical Device Authority (MDA) in Malaysia has approved the company’s implant technologies Episealer® Knee and Episealer® Talus for the Malaysian market. The approval follows a review process. “It is exciting to see the progress of the regulatory work for Episurf’s devices towards new markets. This regulatory approval opens up the market and enables us to work with our distributor towards the next important steps in Malaysia“, says Michael Näsström, Head of Quality and Regulatory Affairs at Episurf Medical.

Wulff Group Plc´s new Chief Financial Officer

STOCK EXCHANGE RELEASE | JANUARY 17, 2022 AT 9.30 A.M. Wulff Group Plc’s current CFO and member of the Executive Board, Elina Hanén, MSc is resigning from her position. Wulff Group Plc’s new CFO and member of the Executive Board from 1 February onwards will be Atte Ailio, MSc. He will be responsible for the economic and financial management of Wulff Group. Ailio will be reporting to the company’s CEO Elina Pienimäki.  Atte Ailio has extensive experience from economic and financial management tasks in multiple sectors. His diverse experience of M&A and financing provides him with an

Jens Lindberg takes office as CEO of Medivir on January 24

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that Jens Lindberg will assume his position as CEO on January 24, 2022. Magnus Christensen, who has been interim CFO since the Annual General Meeting on May 5, 2021 will remain as CFO of Medivir. Jens Lindberg joins Medivir from his current position as VP Commercial at Sedana Medical, where he also served as acting CEO of the company during Q2-Q3 2021. Prior to that, during his twenty-five years at AstraZeneca, Jens held numerous roles, spanning local and global areas of responsibility. In the later years at

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 14th January 2022, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 27,054,136 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

New European patent approval for Episurf Medical

The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “Tools for assisting in osteotomy procedures, and methods for designing osteotomy tools” relates to surgical instruments in Episurf Medical’s Episealer® Talus technology for the ankle. “The patent covers Episurf’s individualised osteotomy guide, developed for optimised clinical outcomes when treating difficult to reach ankle lesions. This device is an important part of the Episealer® Talus technology”, comments Katarina Flodström, COO,

Invitation to SSAB’s year-end report 2021 briefing

SSAB invites you to a presentation of the year-end report for 2021 at 9.30am CET on Friday, January 28, 2022. The briefing will take place by combined webcast and conference call that will be webcast on SSAB’s website. The report will be published at approximately 7.30am CET on the same date.The year-end report will be presented by SSAB’s President and CEO Martin Lindqvist, and CFO Leena Craelius. The briefing will be held in English. Time of briefing: Friday, January 28, 2022 at 9.30am CET. Teleconference numbers:Sweden:                        +46 856 6426 51United Kingdom:

CapMan Nordic Property Income Fund (non-UCITS) acquires a warehouse asset close to Gothenburg further strengthening fund’s exposure to light industrial assets

CapMan Real Estate press release 17 January 2022 at 09:00 AM EET CapMan Nordic Property Income Fund (non-UCITS) acquires a warehouse asset close to Gothenburg further strengthening fund’s exposure to light industrial assets CapMan Nordic Property Income fund (“CMNPI”) has acquired a warehouse asset consisting of two adjacent properties in Mölnlycke Företagspark, Sweden, east of Gothenburg. One of the properties is a fully developed warehouse property of approximately 7,000 square metres which was completed in 2018 and the other one is an undeveloped land plot with

Enhertu granted Priority Review for breast cancer

17 January 2022 07:00 GMT Enhertu granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen Based on ground-breaking DESTINY-Breast03 results showing AstraZeneca and Daiichi Sankyo's Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) Application being evaluated under FDA Real-Time Oncology Review and Project Orbis AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (

There are no items matching the current filter
There are no more items matching the current filter
Back to top